Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 5, 2006, Pages 1068-1073

  Sobue, Satoshi ^a   Sekiguchi, Kaneo ^a   Kikkawa, Hironori ^a   Akasaki, Moriaki ^a   Irie, Shin ^b  

^a PFIZER INC   (United States)

^b LTA Medical Corporation   (Japan)

Author keywords

Cigarette smoking; Linearity; Nicotine; Pharmacokinetics; Transdermal

Indexed keywords

NICOTINE; NICOTINE GUM; NICOTINE PATCH; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; ERYTHEMA; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; PRURITUS;

ADMINISTRATION, CUTANEOUS; ADULT; COHORT STUDIES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; SMOKING;

EID: 33646462879     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1068     Document Type: Article

References (39)

1. Stolerman I. P., Jarvis M. J., Psychopharmacology (Berl), 117, 2-10, discussion 14-20 (1995).
2. Gourlay S. G., Benowitz N. L., Clin. Pharmacol. Ther., 62, 453-463 (1997).
3. Henningfield J. E., Keenan R. M., J. Consult. Clin. Psychol., 61, 743-750 (1993).
4. Le Houezec J., Int. J. Tuberc. Lung Dis., 7, 811-819 (2003).
5. Silagy C., Lancaster T., Stead L., Mant D., Fowler G., Cochrane. Database Syst. Rev., 3, CD 000146 (2004).
6. Hajek P., West R., Foulds J., Nilsson F., Burrows S., Meadow A., Arch. Intern. Med., 159, 2033-2038 (1999).
7. Hukkanen J., Jacob P., 3rd, Benowitz N. L., Pharmacol. Rev., 57, 79-115 (2005).
8. Travell J., Ann. N.Y. Acad. Sci., 90, 13-30 (1960).
9. Gore A. V., Chien Y. W., Clin. Dermatol., 16, 599-615 (1998).
10. Feyerabend C., Levitt T., Russell M. A., J. Pharm. Pharmacol., 27, 433-436 (1975).
11. Pacifici R., Pichini S., Altieri I., Rosa M., Bacosi A., Caronna A., Zuccaro P., J. Chromatogr., 612, 209-213 (1993).
12. Rustemeier K., Demetriou D., Schepers G., Voncken P., J. Chromatogr., 613, 95-103 (1993).
13. Kochak G. M., Sun J. X., Choi R. L., Piraino A. J., Pharm. Res., 9, 1451-1455 (1992).
14. Urae A., Irie S., Amamoto T., Yoshiie H., J. Clin. Therap. Med., 10, S3-S34 (1994).
15. Dubois J. P., Sioufi A., Muller P., Mauli D., Imhof P. R., Methods Find. Exp. Clin. Pharmacol., 11, 187-195 (1989).
16. Gorsline J., Gupta S. K., Dye D., Rolf C. N., J. Clin. Pharmacol., 33, 161-168 (1993).
17. Lawson G. M., Hurt R. D., Dale L. C., Offord K. P., Croghan I. T., Schroeder D. R., Jiang N. S., J. Clin. Pharmacol., 38, 502-509 (1998).
18. Lawson G. M., Hurt R. D., Dale L. C., Offord K. P., Croghan I. T., Schroeder D. R., Jiang N. S., J. Clin. Pharmacol., 38, 510-516 (1998).
19. Bannon Y. B., Corish J., Corrigan O. I., Devane J. G., Kavanagh M., Mulligan S., Eur. J. Clin. Pharmacol., 37, 285-290 (1989).
20. Malaiyandi V., Sellers E. M., Tyndale R. F., Clin. Pharmacol. Ther., 77, 145-158 (2005).
21. Kim K., Johnson J. A., Derendorf H., J. Clin. Pharmacol., 44, 1083-1105 (2004).
22. Guy R. H., Hadgraft J., "Percutaneous Absorption: Mechanisms-Methodology-Drug Delivery," ed. by Bronaugh R. L., Maibach H. I., Marcel Dekker, New York, 1989, pp. 13-26.
23. Sobue S., Sekiguchi K., Kikkawa H., Irie S., J. Clin. Pharmacol., 45, 1391-1399 (2005).
24. Gupta S. K., Hwang S. S., Causey D., Rolf C. N., Gorsline J., J. Clin. Pharmacol., 35, 985-989 (1995).
25. Benowitz N. L., Zevin S., Jacob P., 3rd, Br. J. Clin. Pharmacol., 43, 259-267 (1997).
26. Benowitz N. L., Drugs, 45, 157-170 (1993).
27. Schneider N. G., Olmstead R. E., Franzon M. A., Lunell E., Clin. Pharmacokinet., 40, 661-684 (2001).
28. Benowitz N. L., NIDA Res. Monogr., 99, 12-29 (1990).
29. Russell M. A., Jarvis M., Iyer R., Feyerabend C., Br. Med. J., 280, 972-976 (1980).
30. Benowitz N. L., Hall S. M., Herning R. I., Jacob P., 3rd., Jones R. T., Osman A. L., N. Engl. J. Med., 309, 139-142 (1983).
31. Jarvis M. J., Boreham R., Primatesta P., Feyerabend C., Bryant A., J. Natl. Cancer Inst., 93, 134-138 (2001).
32. Hecht S. S., Murphy S. E., Carmella S. G., Li S., Jensen J., Le C., Joseph A. M., Hatsukami D. K., Cancer Epidemiol. Biomarkers Prev., 14, 693-698 (2005).
33. Benowitz N. L., Porchet H., Jacob P., 3rd., "Nicotine Psychopharmacology: Molecular, Cellular and Behavioral Aspects," ed. by Wonnacot S., Russell M. A. H., Stolerman I. P., Oxford University Press, Oxford, 1990, pp. 112-157.
34. Benowitz N. L., Jacob P., 3rd, Savanapridi C., Clin. Pharmacol. Ther., 41, 467-473 (1987).
35. Lunell E., Molander L., Leischow S. J., Fagerstrom K. O., Eur. J. Clin. Pharmacol., 48, 235-240 (1995).
36. Russell M. A., Sutton S. R., Feyerabend C., Cole P. V., Saloojee Y., Br. Med. J., 1, 1060-1063 (1977).
37. Russell M. A., Jarvis M. J., NIDA Res. Monogr., 53, 110-130 (1985).
38. Patterson F., Benowitz N., Shields P., Kaufmann V., Jepson C., Wileyto P., Kucharski S., Lerman C., Cancer Epidemiol. Biomarkers Prev., 12, 468-471 (2003).
39. Thompson G. H., Hunter D. A., Ann. Pharmacother., 32, 1067-1075 (1998).